Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T61722
(Former ID: TTDC00237)
|
|||||
| Target Name |
Prostaglandin D2 receptor 2 (PTGDR2)
|
|||||
| Synonyms |
PTGDR2; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CD294
Click to Show/Hide
|
|||||
| Gene Name |
PTGDR2
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Coronary atherosclerosis [ICD-11: BA80] | |||||
| Function |
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin- sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Receptoractivation is responsible, at least in part, in immune regulation and allergic/inflammation responses.
Click to Show/Hide
|
|||||
| BioChemical Class |
GPCR rhodopsin
|
|||||
| UniProt ID | ||||||
| Sequence |
MSANATLKPLCPILEQMSRLQSHSNTSIRYIDHAAVLLHGLASLLGLVENGVILFVVGCR
MRQTVVTTWVLHLALSDLLASASLPFFTYFLAVGHSWELGTTFCKLHSSIFFLNMFASGF LLSAISLDRCLQVVRPVWAQNHRTVAAAHKVCLVLWALAVLNTVPYFVFRDTISRLDGRI MCYYNVLLLNPGPDRDATCNSRQVALAVSKFLLAFLVPLAIIASSHAAVSLRLQHRGRRR PGRFVRLVAAVVAAFALCWGPYHVFSLLEARAHANPGLRPLVWRGLPFVTSLAFFNSVAN PVLYVLTCPDMLRKLRRSLRTVLESVLVDDSELGGAGSSRRRRTSSTARSASPLALCSRP EEPRGPARLLGWLLGSCAASPQTGPLNRALSSTSS Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 11 Clinical Trial Drugs | + | ||||
| 1 | Setipiprant | Drug Info | Phase 3 | Asthma | [4] | |
| 2 | Ramatroban | Drug Info | Phase 2/3 | Perennial allergic rhinitis | [5], [6] | |
| 3 | ADC-3680 | Drug Info | Phase 2 | Allergic rhinitis | [11] | |
| 4 | AP-761 | Drug Info | Phase 2 | Asthma | [12] | |
| 5 | ARRY-502 | Drug Info | Phase 2 | Allergic asthma | [13] | |
| 6 | AZD1981 | Drug Info | Phase 2 | Chronic obstructive pulmonary disease | [14], [15] | |
| 7 | QAV-680 | Drug Info | Phase 2 | Allergic rhinitis | [16] | |
| 8 | AM-211 | Drug Info | Phase 1 | Asthma | [17] | |
| 9 | AM-461 | Drug Info | Phase 1 | Respiratory disease | [18] | |
| 10 | MK-7246 | Drug Info | Phase 1 | Respiratory disease | [19] | |
| 11 | PGF2alpha | Drug Info | Clinical trial | Solid tumour/cancer | [20] | |
| Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
| 1 | AZD5985 | Drug Info | Discontinued in Phase 1 | Chronic obstructive pulmonary disease | [21] | |
| 2 | AZD8075 | Drug Info | Discontinued in Phase 1 | Chronic obstructive pulmonary disease | [22] | |
| 3 | RG-7185 | Drug Info | Discontinued in Phase 1 | Asthma | [23] | |
| Mode of Action | [+] 4 Modes of Action | + | ||||
| Antagonist | [+] 12 Antagonist drugs | + | ||||
| 1 | Setipiprant | Drug Info | [24] | |||
| 2 | Ramatroban | Drug Info | [25] | |||
| 3 | ADC-3680 | Drug Info | [26] | |||
| 4 | AP-761 | Drug Info | [27] | |||
| 5 | AZD1981 | Drug Info | [29] | |||
| 6 | QAV-680 | Drug Info | [30] | |||
| 7 | AM-211 | Drug Info | [31] | |||
| 8 | AM-461 | Drug Info | [32] | |||
| 9 | AZD5985 | Drug Info | [29] | |||
| 10 | AZD8075 | Drug Info | [29] | |||
| 11 | RG-7185 | Drug Info | [35] | |||
| 12 | AM-156 | Drug Info | [42] | |||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | ARRY-502 | Drug Info | [28] | |||
| 2 | MK-7246 | Drug Info | [33] | |||
| Agonist | [+] 10 Agonist drugs | + | ||||
| 1 | PGF2alpha | Drug Info | [34] | |||
| 2 | 13,14-dihydro-15-keto-PGD2 | Drug Info | [25] | |||
| 3 | 15(R)-15-methyl-PGD2 | Drug Info | [25] | |||
| 4 | 15(S)-15-methyl-PGD2 | Drug Info | [36] | |||
| 5 | 15-deoxy-Delta12,14-PGD2 | Drug Info | [34] | |||
| 6 | 15-deoxy-Delta12,14-PGJ2 | Drug Info | [34] | |||
| 7 | CAY 10471 | Drug Info | [43] | |||
| 8 | Delta12-PGJ2 | Drug Info | [36] | |||
| 9 | PGD2 | Drug Info | [25], [45] | |||
| 10 | U46619 | Drug Info | [36] | |||
| Inhibitor | [+] 20 Inhibitor drugs | + | ||||
| 1 | 2-(2,4-diphenylthiazol-5-yl)acetic acid | Drug Info | [37] | |||
| 2 | 2-(2-acetyl-4-bromophenoxy)acetic acid | Drug Info | [38] | |||
| 3 | 2-(2-allyl-4-chlorophenoxy)acetic acid | Drug Info | [39] | |||
| 4 | 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid | Drug Info | [40] | |||
| 5 | 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid | Drug Info | [39] | |||
| 6 | 2-(2-cyclohexyl-4-methylphenoxy)acetic acid | Drug Info | [39] | |||
| 7 | 2-(2-cyclohexylphenoxy)acetic acid | Drug Info | [39] | |||
| 8 | 2-(2-formylphenoxy)acetic acid | Drug Info | [38] | |||
| 9 | 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid | Drug Info | [38] | |||
| 10 | 2-(4-bromo-2-cyclohexylphenoxy)acetic acid | Drug Info | [39] | |||
| 11 | 2-(4-bromo-2-formylphenoxy)acetic acid | Drug Info | [38] | |||
| 12 | 2-(4-bromo-2-tert-butylphenoxy)acetic acid | Drug Info | [38] | |||
| 13 | 2-(4-chloro-2-cycloheptylphenoxy)acetic acid | Drug Info | [41] | |||
| 14 | 2-(4-chloro-2-cyclohexylphenoxy)acetic acid | Drug Info | [39] | |||
| 15 | 2-(4-chloro-2-cyclopentylphenoxy)acetic acid | Drug Info | [39] | |||
| 16 | 2-(4-cyano-2-cyclohexylphenoxy)acetic acid | Drug Info | [39] | |||
| 17 | 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid | Drug Info | [39] | |||
| 18 | IW-1221 | Drug Info | [42] | |||
| 19 | L-888607 | Drug Info | [44] | |||
| 20 | Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate | Drug Info | [39] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Fevipiprant | Ligand Info | |||||
| Structure Description | Crystal structure of the prostaglandin D2 receptor CRTH2 with fevipiprant | PDB:6D26 | ||||
| Method | X-ray diffraction | Resolution | 2.80 Å | Mutation | Yes | [46] |
| PDB Sequence |
ATLKPLCPIL
14 EQMSRLQSHS24 ATSIRYIDHA34 AVLLHGLASL44 LGLVENGVIL54 FVVGCRMRQT 64 VVTTWVLHLA74 LSDLLASASL84 PFFTYFLAVG94 HSWELGTTFC104 KLHSSIFFLN 114 MFASGFLLSA124 ISLDRCLQVV134 RPVWAQNHRT144 VAAAHKVCLV154 LWALAVLNTV 164 PYFVFRDTIS174 RLDGRIMCYY184 NVLLLNPGPD194 RDATCNSRQA204 ALAVSKFLLA 214 FLVPLAIIAS224 SHAAVSLRLQ234 HRADLGLQHR1245 NIFEMLRIDE1255 GGGSGGDEAE 1265 KLFNQDVDAA1275 VRGILRNAKL1285 KPVYDSLDAV1295 RRAALINMVF1305 QMGETGVAGF 1315 TNSLRMLQQK1325 RWDEAAVNLA1335 KSRWYNQTPN1345 RAKRVITTFR1355 TGTWDAYRRR 2240 PGRFVRLVAA2250 VVAAFALCWG2260 PYHVFSLLEA2270 RAHANPGLRP2280 LVWRGLPFVT 2290 SLAFFNSVAN2300 PVLYVLTPDM2311 LRKLRRSLRT2321 VLESVL
|
|||||
|
|
MET17
3.503
PHE87
3.385
PHE90
3.643
LEU91
4.881
HIS95
3.659
HIS107
4.303
SER108
4.344
PHE111
3.480
PHE112
3.527
ARG170
2.292
ARG175
3.587
ILE180
4.781
MET181
3.291
|
|||||
| Ligand Name: 15(R)-15-methyl-PGD2 | Ligand Info | |||||
| Structure Description | XFEL crystal structure of the prostaglandin D2 receptor CRTH2 in complex with 15R-methyl-PGD2 | PDB:7M8W | ||||
| Method | X-ray diffraction | Resolution | 2.61 Å | Mutation | Yes | [47] |
| PDB Sequence |
ANATLKPLCP
12 ILEQMSRLQS22 HSATSIRYID32 HAAVLLHGLA42 SLLGLVENGV52 ILFVVGCRMR 62 QTVVTTWVLH72 LALSDLLASA82 SLPFFTYFLA92 VGHSWELGTT102 FCKLHSSIFF 112 LNMFASGFLL122 SAISLDRCLQ132 VVRPVWAQNH142 RTVAAAHKVC152 LVLWALAVLN 162 TVPYFVFRDT172 ISRLDGRIMC182 YYNVLLLNPG192 PDRDATCNSR202 QAALAVSKFL 212 LAFLVPLAII222 ASSHAAVSLR232 LQHRADLGLQ905 HRNIFEEKLF1067 NQDVDAAVRG 1077 ILRNAKLKPV1087 YDSLDAVRRA1097 ALINMVFQMG1107 ETGVAGFTNS1117 LRMLQQKRWD 1127 EAAVNLAKSR1137 WYNQTPNRAK1147 RVITTFRTGT1157 WDAYRRRPGR243 FVRLVAAVVA 253 AFALCWGPYH263 VFSLLEARAH273 ANPGLRPLVW283 RGLPFVTSLA293 FFNSVANPVL 303 YVLTPDMLRK314 LRRSLRTVLE324 SVLVDD
|
|||||
|
|
MET17
4.206
PHE87
3.710
PHE90
3.755
TRP97
3.609
HIS107
3.525
SER108
4.084
PHE111
3.489
PHE112
3.218
ARG170
2.483
ARG175
4.542
MET181
3.835
CYS182
2.807
|
|||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| Reactome | [+] 2 Reactome Pathways | + | ||||
| 1 | Prostanoid ligand receptors | |||||
| 2 | G alpha (i) signalling events | |||||
| WikiPathways | [+] 3 WikiPathways | + | ||||
| 1 | GPCRs, Class A Rhodopsin-like | |||||
| 2 | GPCR ligand binding | |||||
| 3 | GPCR downstream signaling | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. | |||||
| REF 2 | ClinicalTrials.gov (NCT01126073) A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin in Miran Sebestjen, University Medical Centre Ljubljana. | |||||
| REF 3 | ClinicalTrials.gov (NCT03226392) Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT01484119) Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis. U.S. National Institutes of Health. | |||||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1911). | |||||
| REF 6 | ClinicalTrials.gov (NCT00311051) Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite. U.S. National Institutes of Health. | |||||
| REF 7 | ClinicalTrials.gov (NCT01056783) Proof of Concept Study of OC000459 in Eosinophilic Esophagitis. U.S. National Institutes of Health. | |||||
| REF 8 | ClinicalTrials.gov (NCT01018550) AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma. U.S. National Institutes of Health. | |||||
| REF 9 | ClinicalTrials.gov (NCT02590289) A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects. U.S. National Institutes of Health. | |||||
| REF 10 | ClinicalTrials.gov (NCT03683576) A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma. U.S.National Institutes of Health. | |||||
| REF 11 | ClinicalTrials.gov (NCT01448954) A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma. U.S. National Institutes of Health. | |||||
| REF 12 | ClinicalTrials.gov (NCT01007721) Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season. U.S. National Institutes of Health. | |||||
| REF 13 | ClinicalTrials.gov (NCT01561690) A Study of ARRY-502 in Patients With Persistent Asthma. U.S. National Institutes of Health. | |||||
| REF 14 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7680). | |||||
| REF 15 | ClinicalTrials.gov (NCT00766415) 14729-D9831C00002- 1 Month Biopsy Study. U.S. National Institutes of Health. | |||||
| REF 16 | ClinicalTrials.gov (NCT01103037) Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma. U.S. National Institutes of Health. | |||||
| REF 17 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030063) | |||||
| REF 18 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031337) | |||||
| REF 19 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031315) | |||||
| REF 20 | Stereocontrolled organocatalytic synthesis of prostaglandin PGF2alpha in seven steps. Nature. 2012 Sep 13;489(7415):278-81. | |||||
| REF 21 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029299) | |||||
| REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029210) | |||||
| REF 23 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033115) | |||||
| REF 24 | Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52. | |||||
| REF 25 | CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. | |||||
| REF 26 | Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. | |||||
| REF 27 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464) | |||||
| REF 28 | Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502). | |||||
| REF 29 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||||
| REF 30 | Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91. | |||||
| REF 31 | Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011 Jul;338(1):290-301. | |||||
| REF 32 | A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat. 2011 Dec;21(12):1931-6. | |||||
| REF 33 | Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. | |||||
| REF 34 | Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. | |||||
| REF 35 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033115) | |||||
| REF 36 | Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. | |||||
| REF 37 | Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1177-80. | |||||
| REF 38 | Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. | |||||
| REF 39 | 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. | |||||
| REF 40 | Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1181-5. | |||||
| REF 41 | 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4794-8. | |||||
| REF 42 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339). | |||||
| REF 43 | Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem. 2005 Feb 24;48(4):897-900. | |||||
| REF 44 | Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. J Med Chem. 2005 Oct 6;48(20):6174-7. | |||||
| REF 45 | On the mechanism of interaction of potent surmountable and insurmountable antagonists with the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2006 Apr;69(4):1441-53. | |||||
| REF 46 | Structures of the Human PGD(2) Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition. Mol Cell. 2018 Oct 4;72(1):48-59.e4. | |||||
| REF 47 | Molecular basis for lipid recognition by the prostaglandin D(2) receptor CRTH2. Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):e2102813118. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.